Perspectives in the prevention and treatment of acute graft versus host disease.
Herve
P
P
BMT Unit, Besancon, France.
D000208:Acute Disease; D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D015703:Antigens, CD / Q000276:immunology; D016026:Bone Marrow Transplantation / Q000009:adverse effects*; D018956:CD5 Antigens; D003115:Colony-Stimulating Factors / Q000627:therapeutic use; D006086:Graft vs Host Disease / Q000209:etiology / Q000517:prevention & control* / Q000628:therapy; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use; D007165:Immunosuppression Therapy / Q000379:methods*; D000922:Immunotoxins / Q000627:therapeutic use; D007938:Leukemia / Q000601:surgery; D008212:Lymphocyte Depletion; D008222:Lymphokines / Q000627:therapeutic use; D051379:Mice; D009364:Neoplasm Recurrence, Local / Q000517:prevention & control; D015375:Receptors, Interleukin-2 / Q000276:immunology; D013601:T-Lymphocytes / Q000276:immunology; D014409:Tumor Necrosis Factor-alpha / Q000276:immunology
D000305:Adrenal Cortex Hormones; D000911:Antibodies, Monoclonal; D015703:Antigens, CD; D018956:CD5 Antigens; D003115:Colony-Stimulating Factors; D007155:Immunologic Factors; D000922:Immunotoxins; D008222:Lymphokines; D015375:Receptors, Interleukin-2; D014409:Tumor Necrosis Factor-alpha